Temenos Launches SaaS Explainable AI Models to Help Banks Support Small Businesses and Retail Customers During COVID-19 Crisis
23.4.2020 09:30:00 EEST | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, announced today the launch of Explainable AI (XAI) models to enable banks and credit unions to rapidly offer loans to small and medium enterprises (SMEs) that have seen their cash flow disrupted by the COVID-19 outbreak. These patented XAI models allow banks to accelerate digital onboarding, conduct eligibility checks and process loan applications for SMEs and retail customers. The models are available as part of the Temenos AI portfolio or can be integrated with Temenos Infinity, the leading digital omnichannel product, and are delivered as Temenos SaaS for fast and scalable deployment.
Max Chuard, Chief Executive Officer, Temenos, said: “These are challenging times for small businesses in particular. As the leader in banking software, Temenos is committed to innovation that not only keeps banks and the global economy running, but also helps SMEs and retail customers access funding at a time of financial distress. We are delivering our cloud-native, advanced AI banking software as SaaS to enable banks qualify and process loans rapidly. I am proud that with our technology we can provide banks with a modern digital banking platform and decision-making capabilities, allowing them to move incredibly fast and compress projects that would usually take months into days.”
Temenos’ XAI models help banks make urgent lending decisions that are transparent and explainable in human language to the end-users, customers and the regulators. These models enable banks to identify appropriate products that carry an acceptable level of risk for both the customer and the bank. The SME model, in particular, provides on average over 25% greater accuracy compared to the risk score provided by leading credit bureaus, allowing banks to increase their pass rate by 20% while keeping defaults under control.
The new XAI models enable banks to take into account a wide range of variables when making lending decisions, such as additional incomes, new cost reductions, and alternative forms of collateral. Temenos XAI models can instantly calculate the impact of new variables and suggest additional terms and conditions.
As a result of the pandemic, banks are being asked to lend in unusual circumstances, requiring them to manage the twin pressures of increasing arrears and political pressure not to trigger defaults. Government Initiatives like the UK Coronavirus Business Interruption Loan Scheme (CBILS) and the US Paycheck Protection Program (PPP) are aiming to help SMEs in need of financial support by promoting emergency bank loans.
Jerry Silva, Research Vice President, IDC, said: “A record number of small businesses and individuals are now applying for loans and financial relief. In the face of this demand, banks need to respond by providing digital self-service user journeys, quickly conducting eligibility checks, adhering to bank risk criteria, and establishing appropriate pricing. Solutions like Temenos’ new XAI models are designed to help banks accelerate the loan application process by centralizing and enforcing policy rules using AI to ensure decisions are based on bank-specified criteria while maintaining transparency with customers and maintaining compliance and risk controls.”
These API-driven XAI models can be rolled out with the associated policy rules, allowing smart decision-making with minimal integration that can be deployed in the cloud in days or just a few weeks. This consistency in decision-making helps frontline staff by reducing the need for manual intervention, which can slow the processing of the huge volumes of applications being considered. Temenos’ XAI models can be used by any business user with minimum reliance on the IT department.
The XAI models available worldwide include:
- Temenos AI – SME Smart Decisioning: Temenos provides centrally created support for decision makers at the front line, for on-boarding, edibility checks and rapid loan processing. Furthermore, it reduces the need for human intervention in underwriting departments. The model is already proven with blue-chip UK lenders and can rapidly augment the decision-making processes already in place.
- Temenos AI – Urgent Relief Loan: Identify customers with a significant drop in income, who are at financial risk and offer further credit or credit deferral products.
- Temenos AI – Personalization: Offer personalized products to customers in real-time based on their changing behaviors and needs identified using Explainable AI models
- Temenos AI – Loan Pre-Approvals: Lending pre-approval for all customers. Expedite short- term urgent lending to the greatest number of customers.
- Temenos AI – Digital Financial Advice: Identify customers who are unlikely to be able to continue without finding a new source of income, hence both reducing risk and offering the opportunity to provide suitable financial solutions to them.
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200422005802/en/
Contact information
Jessica Wolfe & Grace Collins
Temenos Global Public Relations
Tel: +1 610 232 2793 & + 44 20 7423 3969
Email : press@temenos.com
Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email: allnewgatetemenos@newgatecomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 11:22:00 EET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
